Roche is investigating a case of a German patient diagnosed with a deadly brain infection called PML after taking one dose of the company’s new MS drug Ocrevus.

November 5, 2015By Mark Terry, BioSpace.com Breaking News Staff   After Cambridge, Mass.-based Biogen, Inc. (BIIB) presented its research and development ambitions on Tuesday, analysts have started examining the company’s strategy. On Oct. 21, 2015, Biogen released its third-quarter financials which included $2.8 billion in revenues, an 11 percent increase compared to the third quarter […]

Cambridge, Mass.-based Biogen, Inc. (BIIB) announced today that it was restructuring, cutting 11 percent of its workforce, and slashing programs. In addition, the company announced that its Phase III ASCEND clinical trial of natalizumab for the treatment of secondary progressive multiple sclerosis (SPMS) failed to hit its primary and secondary endpoints. As part of the […]